Cargando…

PARP-1/2 Inhibitor Olaparib Prevents or Partially Reverts EMT Induced by TGF-β in NMuMG Cells

Poly- adenosine diphosphate (ADP)-ribose (PAR) is a polymer synthesized as a posttranslational modification by some poly (ADP-ribose) polymerases (PARPs), namely PARP-1, PARP-2, tankyrase-1, and tankyrase-2 (TNKS-1/2). PARP-1 is nuclear and has also been detected in extracellular vesicles. PARP-2 an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schacke, Michelle, Kumar, Janani, Colwell, Nicholas, Hermanson, Kole, Folle, Gustavo A., Nechaev, Sergei, Dhasarathy, Archana, Lafon-Hughes, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387051/ https://www.ncbi.nlm.nih.gov/pubmed/30691122 http://dx.doi.org/10.3390/ijms20030518

Ejemplares similares

Par6 is an essential mediator of apoptotic response to transforming growth factor beta in NMuMG immortalized mammary cells
por: Avery-Cooper, Geordon, et al.
Publicado: (2014)

Tension Monitoring during Epithelial-to-Mesenchymal Transition Links the Switch of Phenotype to Expression of Moesin and Cadherins in NMuMG Cells
por: Schneider, David, et al.
Publicado: (2013)

Suppression of TGFβ-Induced Epithelial-Mesenchymal Transition Like Phenotype by a PIAS1 Regulated Sumoylation Pathway in NMuMG Epithelial Cells
por: Netherton, Stuart J., et al.
Publicado: (2010)

PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors
por: Perini, Valentina, et al.
Publicado: (2020)

The calcium channel proteins ORAI3 and STIM1 mediate TGF-β induced Snai1 expression
por: Bhattacharya, Atrayee, et al.
Publicado: (2018)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
por: Mao, Yize, et al.
Publicado: (2018)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2015)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

PET Imaging of PARP Expression Using (18)F-Olaparib
por: Wilson, Thomas C., et al.
Publicado: (2019)

Neuromedins NMU and NMS: An Updated Overview of Their Functions
por: Malendowicz, Ludwik K., et al.
Publicado: (2021)

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib()
por: Wang, Chen, et al.
Publicado: (2017)

Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
por: Osoegawa, Atsushi, et al.
Publicado: (2017)

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2017)

Olaparib‐Based Photoaffinity Probes for PARP‐1 Detection in Living Cells
por: Voorneveld, Jim, et al.
Publicado: (2020)

PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
por: Liu, Chuan, et al.
Publicado: (2020)

NMUR1 in the NMU-Mediated Regulation of Bone Remodeling
por: Hsiao, Yu-Tin, et al.
Publicado: (2021)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
por: Park, Hye Jeong, et al.
Publicado: (2018)

PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation
por: Kageyama, Shun-ichiro, et al.
Publicado: (2020)

Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib
por: Gross, Maya, et al.
Publicado: (2022)

NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma
por: Tang, Yan, et al.
Publicado: (2021)

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
por: Daemen, Anneleen, et al.
Publicado: (2012)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
por: Qin, Hongyu, et al.
Publicado: (2023)

RNA polymerase II pausing can be retained or acquired during activation of genes involved in the epithelial to mesenchymal transition
por: Samarakkody, Ann, et al.
Publicado: (2015)

Histological analysis of low dose NMU effects in the rat mammary gland
por: Murray, Tessa J, et al.
Publicado: (2009)

Expression of NMU, PPBP and GNG4 in colon cancer and their influences on prognosis
por: Chen, Danyu, et al.
Publicado: (2022)

The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions
por: Orta, Manuel Luis, et al.
Publicado: (2014)

JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib
por: YANG, XUELI, et al.
Publicado: (2015)

PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
por: Yang, Xiao-Dong, et al.
Publicado: (2021)

PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cells
por: Qin, Changjiang, et al.
Publicado: (2022)

MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib
por: Bonciarelli, Stefano, et al.
Publicado: (2023)

Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma
por: Jiang, Ruixin, et al.
Publicado: (2022)

Proceedings: Immunosuppressive activity of N-nitroso-N-methylurea (NMU) and dimethylnitrosamine (DMN).
por: Waynforth, H. B., et al.
Publicado: (1974)

NMU signaling promotes endometrial cancer cell progression by modulating adhesion signaling
por: Lin, Ting-Yu, et al.
Publicado: (2016)

Examining the Role of Hypothalamus-Derived Neuromedin-U (NMU) in Bone Remodeling of Rats
por: Born-Evers, Gabriella, et al.
Publicado: (2023)

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
por: de Haan, R., et al.
Publicado: (2019)

Effects of the PARP Inhibitor Olaparib on the Response of Human Peripheral Blood Leukocytes to Bacterial Challenge or Oxidative Stress
por: Santos, Sidneia Sousa, et al.
Publicado: (2022)

Effectiveness of combined limonene and 4-hydroxyandrostenedione in the treatment of NMU-induced rat mammary tumours.
por: Chander, S. K., et al.
Publicado: (1994)

Evaluation of NMU-Induced Breast Cancer Treated with Sirolimus and Sunitinib on Breast Cancer Growth
por: Jaffar, Nurul Fathiyatul Nabila, et al.
Publicado: (2020)

Peripheral Administration of NMU Promotes White Adipose Tissue Beiging and Improves Glucose Tolerance
por: Yuan, Yue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8ol1mprjtdpf4mr9ig3mefcolp